KNTE
KINNATE BIOPHARMA INC
1 day chart
About KNTE
Kinnate Biopharma Inc. is a clinical-stage precision oncology company. It is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. It is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).
Buy US stocks in Australia starting with KNTE. Open an account and start investing today!
$102.71
-
0.00%
473.98K
$2.25
$2.15
$2.21
$8.17
$1.04
KNTE FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in KNTE
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.